Coverage
-
June 27, 2017
Bristol-Myers Squibb and Sanofi have escaped a whistleblower False Claims Act suit accusing them of prompting Medicaid overbilling through deceptive marketing of the blood thinner Plavix, after a New Jersey federal judge ruled Tuesday that automatic payment requirements made any implied certifications regarding the drug's effectiveness immaterial to payment.
3 other articles on this case.
View all »